ArticleEplasty2024
Simultaneous Sentinel Lymph Node Biopsies Using Both the Magtrace/Sentimag System and Radioactive Isotope Tracer/Blue Dye Dual Technique for Concurrent Breast Carcinoma and Malignant Melanoma.
Article in Eplasty, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer and melanoma are extremely common, with a growing incidence in the United Kingdom. In this case report, we present a patient with synchronous melanoma and breast carcinoma, with focus on the simultaneous use of 2 sentinel lymph node biopsy mapping techniques. Methods: The use of 2 mapping techniques in this case is necessary to ensure the accurate identification of the correct sentinel node (for each respective primary malignancy), providing vital prognostic information and allowing for appropriate adjuvant therapy. The report describes the use of a single surgical incision to access both melanoma and breast carcinoma sentinel lymph nodes. Conclusions: The report highlights the technical possibility of using both the radioactive isotope tracer/blue dye dual technique and the Magtrace/Sentimag system without interference or complication.
Indexed as
Identifiers
38846506PMC11155386What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.